Should Canopy Growth Stock Be in Your Portfolio Post Q3 Earnings?

Core Insights - Canopy Growth Corporation (CGC) reported a loss of 1 cent for Q3 fiscal 2026, a significant improvement from a loss of 76 cents in the same period last year, with sales remaining flat at $53.5 million (~C$75 million) [1][11] Financial Performance - Total cannabis revenues increased by 4% year over year, driven by strong performance in the Canadian market, which helped mitigate international volatility [3] - Canadian adult-use market sales rose by 8% year over year, supported by growth in infused pre-roll joints and new All-In-One vapes [4] - Medical cannabis sales in Canada grew by 15%, aided by an increase in insured patients and larger order volumes [4] - Overall gross margins decreased by 300 basis points to 29%, attributed to lower sales of higher-margin cannabis in international markets and increased inventory provisions [6] Market Dynamics - Canopy Growth's international cannabis division faced challenges due to supply-chain issues in Europe, leading to a decline in net revenues from its Storz & Bickel subsidiary [5] - The company anticipates continued strength in its Canadian cannabis business, with innovations in product offerings and expanding distribution [7] - Management expects sequential improvement in Europe as flower supply and strain availability increase, positioning the region as a growth driver [8] Competitive Landscape - Canopy Growth operates in a competitive market with players like Curaleaf Holdings and Tilray Brands, which are also expanding into international markets [9] - Increased competition may lead to aggressive market moves and further consolidation within the sector [9] Stock Performance and Outlook - Canopy Growth's shares have declined by 40% over the past year, compared to a 16% decline in the industry [12] - Management is targeting positive adjusted EBITDA by fiscal 2027, although overall business visibility remains limited due to international uncertainties and competitive pressures [11][16]